Two extended-spectrum ␤-lactamase (ESBL)-producing salmonella isolates, Salmonella enterica serovar Enteritidis and Salmonella enterica serovar Typhimurium, were analyzed. Both isolates produced the CTX-M-3 ESBL; however, their bla CTX-M-3 genes were located on different plasmids. The serovar Typhimurium isolate also expressed another ESBL, SHV-2a, and probably the two ESBL genes had been acquired independently by the strain.
fotaxime (2 g/ml; Polfa Tarchomin, Warsaw, Poland) and nalidixic acid (64 g/ml; Sigma Chemical Company, St. Louis, Mo.). Both isolates produced transconjugants with an efficiency of around 10 Ϫ4 per donor cell. MICs of various antibiotics were evaluated for the isolates and the transconjugants by the agar dilution method according to the NCCLS guidelines (14) . Antimicrobial standards were supplied by the corresponding manufacturers. Both clinical isolates and their transconjugants revealed MIC patterns that are typical for ESBL-producing strains (13) ( Table 2 ). They were characterized by raised MICs of a variety of ␤-lactams, except for cefoxitin and imipenem, and ␤-lactamase inhibitors reduced effectively MICs of ␤-lactams in all combinations tested. Cefotaxime MICs were significantly higher than those of ceftazidime. Apart from ␤-lactams the clinical isolates were also resistant to aminoglycosides and cotrimoxazole, and resistance to these drugs was cotransferred with ␤-lactam resistance to the transconjugants.
␤-Lactamases of the clinical isolates and their transconjugants were visualized by isoelectric focusing (IEF), and their cefotaxime-hydrolyzing activity was detected by the bioassay approach. IEF and the bioassay were performed as described by Bauernfeind et al. (3) , with the use of a Model 111 Mini Cell (Bio-Rad, Hercules, Calif.) for IEF. The concentration of cefotaxime in the bioassay was 2 g/ml. Results of the analyses are shown in Table 1 . Both isolates produced ␤-lactamases with isoelectric points (pIs) of 8.4 and 5.4, and these two enzymes were also found in extracts of the transconjugants. The serovar Typhimurium isolate, 9197, but not its transconjugant, expressed an additional ␤-lactamase with a pI of 7.6. Only enzymes with pIs of 8.4 and 7.6 demonstrated the cefotaxime-hydrolyzing activity under the conditions used in the bioassay (the ␤-lactamase with a pI of 5.4 was probably TEM-1).
Genes coding for the cefotaxime-hydrolyzing ␤-lactamases were detected by PCR in DNA of the clinical isolates. Both isolates were tested for the presence of bla CTX-M genes (supposed to encode the pI 8.4 enzymes), and DNA of serovar Typhimurium 9197 was also checked by PCR specific for a bla SHV gene (likely coding for the ␤-lactamase with a pI of 7.6). PCRs were run as reported previously (6, 11) . Amplicons of the expected size of around 1 kb were obtained in all three cases and subjected to sequencing using an ABI PRISM 310 sequencer (PE Biosystems, Foster City, Calif.). Sequencing was performed as previously described (1, 6, 11) . The results are shown in Table 1 . Coding regions of the two bla CTX-M genes were identical to that of the bla CTX-M-3 gene (11), which indicated that the ␤-lactamase with a pI of 8.4 was CTX-M-3. The bla SHV gene coding region was of the same nucleotide sequence as in the originally reported bla SHV-2a gene (16) , and this revealed that the ESBL with a pI of 7.6 was SHV-2a.
Plasmid DNA was purified from the transconjugants with the use of the QIAGEN Plasmid Midi Kit (QIAGEN, Hilden, Germany) and subjected to the fingerprinting analysis along with all the variants of bla CTX-M-3 gene-carrying plasmids that had been identified before in Enterobacteriaceae isolates in Poland (1). The PstI restrictase (MBI Fermentas, Vilnius, Lithuania) fingerprinting was performed as reported previously (11) . Both transconjugants contained large plasmids (of around 90 to 110 kb) that produced different fingerprints (Table 1 and Fig. 1 ). The plasmid specific for serovar Enteritidis 33/01 had a fingerprint identical to that of the widely spread bla CTX-M-3 gene-carrying plasmid in Poland (variant A1) (1), whereas the molecule present in serovar Typhimurium 9197 demonstrated a unique PstI restriction pattern.
With the two multiresistant serovar Typhimurium and serovar Enteritidis isolates analyzed here and an S. enterica serovar Mbandaka isolate reported elsewhere (21) , Poland has joined the group of countries in which ESBL-producing salmonellae have been described. Both strains produced the CTX-M-3 enzyme, identified originally in 1996 in Citrobacter freundii isolates from a hospital in Warsaw (11) . CTX-M ␤-lactamases have been relatively frequently found in ESBL-producing salmonellae, including CTX-M-2 in Argentina (2), CTX-M-4 in Russia (9), CTX-M-5 in Latvia (4), CTX-M-6 and -7 in Greece (8), and probably CTX-M-9 in Spain (19) . The CTX-M-4 and -5-producing serovar Typhimurium strains caused clonal outbreaks in hospitals in St. Petersburg and Riga, respectively (4, 7, 22) , and serovar Typhimurium strains related to those from St. Petersburg have been also observed in Hungary and Greece (22) .
The CTX-M-3 ␤-lactamase is widely spread in Poland, having been identified in numerous strains of seven Enterobacteriaceae species in 16 medical centers throughout the country (1, 11, 15) . The isolation of CTX-M-3-producing salmonella strains in hospitals in Grajewo and Koszalin has extended the list by two more institutions. The bla CTX-M-3 gene-carrying plasmids of both isolates demonstrated a high transmission potential; moreover, one of these had been observed before in nine hospitals, which suggests its nosocomial origin (1, 11, 15) . These data support the hypothesis that plasmid dissemination has been the major mechanism of the CTX-M-3 spread in Poland (1, 15) . What is noteworthy is that these plasmids also contained a gene coding for another ␤-lactamase (likely TEM-1) and genes responsible for resistance to aminoglycosides and cotrimoxazole. One of the salmonella isolates, apart from CTX-M-3, also produced another ESBL variant, SHV-2a, which had previously never been identified in Poland. Genes coding for the two ESBLs have probably been acquired independently by the strain, as they were located on separate DNA replicons. Such double-ESBL-producer strains, although occasionally reported (1, 5, 20) , are rare, and to our knowledge they have not been observed in salmonella to date.
